Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Published byLee Hensley Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes."— Presentation transcript:

1 Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data are from all European countries included in THAOS. Shown are: the total number of subjects from each country in THAOS, the proportions of each phenotype, and the most common mutation in each country (with its percentage of all subjects in that country). Not shown are: Belgium, three subjects with cardiac + neurologic phenotype (genotypes: Val30Met, Glu54Leu, and Glu74Leu); and Cyprus, one subject with neurologic phenotype (genotype: Val30Met). Note that the most common form of ATTR amyloidosis in Germany and Italy was ATTRwt (41.6% and 34.2% of all subjects, respectively). Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz173, The content of this slide may be subject to copyright: please see the slide notes for details.

2 Figure 2 A Kaplan–Meier survival curve by genotype for subject death
Figure 2 A Kaplan–Meier survival curve by genotype for subject death. The 95% Hall–Wellner bands and Cox proportional ... Figure 2 A Kaplan–Meier survival curve by genotype for subject death. The 95% Hall–Wellner bands and Cox proportional hazards model are adjusted by age and sex (χ<sup>2</sup> log rank: P < 0.0001). Survival curves are from enrolment in THAOS. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz173, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Figure 3 A Kaplan–Meier survival curve by phenotype for subject death
Figure 3 A Kaplan–Meier survival curve by phenotype for subject death. The 95% Hall–Wellner bands and Cox proportional ... Figure 3 A Kaplan–Meier survival curve by phenotype for subject death. The 95% Hall–Wellner bands and Cox proportional hazards model are adjusted by age and sex (χ<sup>2</sup> log rank: P < 0.0001). Survival curves are from enrolment in THAOS. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) For permissions, please article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( Eur Heart J, ehz173, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes."

Similar presentations

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.
Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.
Figure 1 Study flow diagram and definition of clinical response

Figure 1 Study flow diagram and definition of clinical response
Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 Data-selection process

Figure 1 Data-selection process
Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Flow diagram detailing the systematic review process.
Figure 1 Multivariable-adjusted predictors of PAC

Figure 1 Multivariable-adjusted predictors of PAC
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.
Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1 Mechanism of mortality benefit associated with radial access
Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.
Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.
Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.
Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.
Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.

Figure 1 Sources of uncertainty introduced in each stage of the standard modelling approach for estimating ... Figure 1 Sources of uncertainty introduced.
AHA: American Heart Association; ALT: ...

AHA: American Heart Association; ALT: ...
Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.
Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Similar presentations

Ads by Google